Adjuvants to mechanical ventilation for acute respiratory FailureL

Adoption, de-adoption, and factors associated with selection

Laveena Munshi, Hayley B. Gershengorn, Eddy Fan, Hannah Wunsch, Niall D. Ferguson, Therese A. Stukel, Gordon D. Rubenfeld

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Rationale: Adoption and de-adoption of adjuvant strategies to mechanical ventilation for acute respiratory failure (ARF), and factors associated with their selection, have not been extensively evaluated. Objectives: To evaluate change in use of adjuvants to mechanical ventilation for ARF (2008-2013), the impact of landmark publications on adoption and de-adoption, and factors associated with use. Methods: Changes in use of four adjuvants for ARF from 2008 to 2013, the impact of landmark publications on use, and factors associated with use were evaluated with the Premier Database. Extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide, inhaled epoprostenol, and continuous neuromuscular blockading agents (cNMBAs) in adult mechanically ventilated patients were identified on the basis of International Classification of Diseases, Ninth Revision, Clinical Modification codes and billing data. Measurements and Main Results: Among 514,913 patients with ARF, 11,567 (2.3%) were treated with at least one adjuvant. cNMBAs were the most frequently used adjuvants (n = 10,073, 2.1% in capable hospitals), followed by inhaled pulmonary vasodilators (n = 1,878, 1.0% in capable hospitals; 58% nitric oxide), and ECMO (n = 195, 0.2% in capable hospitals). There was an increase inECMOand inhaled epoprostenol over time but no change in nitric oxide or cNMBAs. Segmented regression analysis was used to evaluate whether clinical practice was in accordance with emerging evidence from landmark studies. Using the relevant landmark publication dates, these analyses did not reveal any change in use over time after publication with the exception of inhaled epoprostenol - for which rates of growth decreased over time, possibly in response to the evidence. There was a significant amount of variability in patient and hospital factors associated with use with between adjuvants. Conclusions: Between 2008 and 2013, there was an increase in use of ECMO and inhaled epoprostenol, and no change in use of inhaled nitric oxide or continuous intravenous infusion of a neuromuscular blocking agent. There was considerable variability in patient and hospital factors associated with use across different adjuvants.

Original languageEnglish (US)
Pages (from-to)94-102
Number of pages9
JournalAnnals of the American Thoracic Society
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Artificial Respiration
Neuromuscular Agents
Epoprostenol
Respiratory Insufficiency
Extracorporeal Membrane Oxygenation
Publications
Nitric Oxide
Neuromuscular Blocking Agents
International Classification of Diseases
Vasodilator Agents
Intravenous Infusions
Regression Analysis
Databases
Lung
Growth

Keywords

  • Acute respiratory distress syndrome
  • Epoprostenol
  • Extracorporeal membrane oxygenation
  • Neuromuscular blockade
  • Nitric oxide

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine

Cite this

Adjuvants to mechanical ventilation for acute respiratory FailureL : Adoption, de-adoption, and factors associated with selection. / Munshi, Laveena; Gershengorn, Hayley B.; Fan, Eddy; Wunsch, Hannah; Ferguson, Niall D.; Stukel, Therese A.; Rubenfeld, Gordon D.

In: Annals of the American Thoracic Society, Vol. 14, No. 1, 01.01.2017, p. 94-102.

Research output: Contribution to journalArticle

Munshi, Laveena ; Gershengorn, Hayley B. ; Fan, Eddy ; Wunsch, Hannah ; Ferguson, Niall D. ; Stukel, Therese A. ; Rubenfeld, Gordon D. / Adjuvants to mechanical ventilation for acute respiratory FailureL : Adoption, de-adoption, and factors associated with selection. In: Annals of the American Thoracic Society. 2017 ; Vol. 14, No. 1. pp. 94-102.
@article{fc256daf61ac4f24abcbae39f5812b43,
title = "Adjuvants to mechanical ventilation for acute respiratory FailureL: Adoption, de-adoption, and factors associated with selection",
abstract = "Rationale: Adoption and de-adoption of adjuvant strategies to mechanical ventilation for acute respiratory failure (ARF), and factors associated with their selection, have not been extensively evaluated. Objectives: To evaluate change in use of adjuvants to mechanical ventilation for ARF (2008-2013), the impact of landmark publications on adoption and de-adoption, and factors associated with use. Methods: Changes in use of four adjuvants for ARF from 2008 to 2013, the impact of landmark publications on use, and factors associated with use were evaluated with the Premier Database. Extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide, inhaled epoprostenol, and continuous neuromuscular blockading agents (cNMBAs) in adult mechanically ventilated patients were identified on the basis of International Classification of Diseases, Ninth Revision, Clinical Modification codes and billing data. Measurements and Main Results: Among 514,913 patients with ARF, 11,567 (2.3{\%}) were treated with at least one adjuvant. cNMBAs were the most frequently used adjuvants (n = 10,073, 2.1{\%} in capable hospitals), followed by inhaled pulmonary vasodilators (n = 1,878, 1.0{\%} in capable hospitals; 58{\%} nitric oxide), and ECMO (n = 195, 0.2{\%} in capable hospitals). There was an increase inECMOand inhaled epoprostenol over time but no change in nitric oxide or cNMBAs. Segmented regression analysis was used to evaluate whether clinical practice was in accordance with emerging evidence from landmark studies. Using the relevant landmark publication dates, these analyses did not reveal any change in use over time after publication with the exception of inhaled epoprostenol - for which rates of growth decreased over time, possibly in response to the evidence. There was a significant amount of variability in patient and hospital factors associated with use with between adjuvants. Conclusions: Between 2008 and 2013, there was an increase in use of ECMO and inhaled epoprostenol, and no change in use of inhaled nitric oxide or continuous intravenous infusion of a neuromuscular blocking agent. There was considerable variability in patient and hospital factors associated with use across different adjuvants.",
keywords = "Acute respiratory distress syndrome, Epoprostenol, Extracorporeal membrane oxygenation, Neuromuscular blockade, Nitric oxide",
author = "Laveena Munshi and Gershengorn, {Hayley B.} and Eddy Fan and Hannah Wunsch and Ferguson, {Niall D.} and Stukel, {Therese A.} and Rubenfeld, {Gordon D.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1513/AnnalsATS.201606-438OC",
language = "English (US)",
volume = "14",
pages = "94--102",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Adjuvants to mechanical ventilation for acute respiratory FailureL

T2 - Adoption, de-adoption, and factors associated with selection

AU - Munshi, Laveena

AU - Gershengorn, Hayley B.

AU - Fan, Eddy

AU - Wunsch, Hannah

AU - Ferguson, Niall D.

AU - Stukel, Therese A.

AU - Rubenfeld, Gordon D.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Rationale: Adoption and de-adoption of adjuvant strategies to mechanical ventilation for acute respiratory failure (ARF), and factors associated with their selection, have not been extensively evaluated. Objectives: To evaluate change in use of adjuvants to mechanical ventilation for ARF (2008-2013), the impact of landmark publications on adoption and de-adoption, and factors associated with use. Methods: Changes in use of four adjuvants for ARF from 2008 to 2013, the impact of landmark publications on use, and factors associated with use were evaluated with the Premier Database. Extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide, inhaled epoprostenol, and continuous neuromuscular blockading agents (cNMBAs) in adult mechanically ventilated patients were identified on the basis of International Classification of Diseases, Ninth Revision, Clinical Modification codes and billing data. Measurements and Main Results: Among 514,913 patients with ARF, 11,567 (2.3%) were treated with at least one adjuvant. cNMBAs were the most frequently used adjuvants (n = 10,073, 2.1% in capable hospitals), followed by inhaled pulmonary vasodilators (n = 1,878, 1.0% in capable hospitals; 58% nitric oxide), and ECMO (n = 195, 0.2% in capable hospitals). There was an increase inECMOand inhaled epoprostenol over time but no change in nitric oxide or cNMBAs. Segmented regression analysis was used to evaluate whether clinical practice was in accordance with emerging evidence from landmark studies. Using the relevant landmark publication dates, these analyses did not reveal any change in use over time after publication with the exception of inhaled epoprostenol - for which rates of growth decreased over time, possibly in response to the evidence. There was a significant amount of variability in patient and hospital factors associated with use with between adjuvants. Conclusions: Between 2008 and 2013, there was an increase in use of ECMO and inhaled epoprostenol, and no change in use of inhaled nitric oxide or continuous intravenous infusion of a neuromuscular blocking agent. There was considerable variability in patient and hospital factors associated with use across different adjuvants.

AB - Rationale: Adoption and de-adoption of adjuvant strategies to mechanical ventilation for acute respiratory failure (ARF), and factors associated with their selection, have not been extensively evaluated. Objectives: To evaluate change in use of adjuvants to mechanical ventilation for ARF (2008-2013), the impact of landmark publications on adoption and de-adoption, and factors associated with use. Methods: Changes in use of four adjuvants for ARF from 2008 to 2013, the impact of landmark publications on use, and factors associated with use were evaluated with the Premier Database. Extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide, inhaled epoprostenol, and continuous neuromuscular blockading agents (cNMBAs) in adult mechanically ventilated patients were identified on the basis of International Classification of Diseases, Ninth Revision, Clinical Modification codes and billing data. Measurements and Main Results: Among 514,913 patients with ARF, 11,567 (2.3%) were treated with at least one adjuvant. cNMBAs were the most frequently used adjuvants (n = 10,073, 2.1% in capable hospitals), followed by inhaled pulmonary vasodilators (n = 1,878, 1.0% in capable hospitals; 58% nitric oxide), and ECMO (n = 195, 0.2% in capable hospitals). There was an increase inECMOand inhaled epoprostenol over time but no change in nitric oxide or cNMBAs. Segmented regression analysis was used to evaluate whether clinical practice was in accordance with emerging evidence from landmark studies. Using the relevant landmark publication dates, these analyses did not reveal any change in use over time after publication with the exception of inhaled epoprostenol - for which rates of growth decreased over time, possibly in response to the evidence. There was a significant amount of variability in patient and hospital factors associated with use with between adjuvants. Conclusions: Between 2008 and 2013, there was an increase in use of ECMO and inhaled epoprostenol, and no change in use of inhaled nitric oxide or continuous intravenous infusion of a neuromuscular blocking agent. There was considerable variability in patient and hospital factors associated with use across different adjuvants.

KW - Acute respiratory distress syndrome

KW - Epoprostenol

KW - Extracorporeal membrane oxygenation

KW - Neuromuscular blockade

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=85008400018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008400018&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201606-438OC

DO - 10.1513/AnnalsATS.201606-438OC

M3 - Article

VL - 14

SP - 94

EP - 102

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 1

ER -